source
- FDA warns of secondary cancers linked to tazemetostat in follicular lymphoma and epithelioid sarcomaThe FDA issued an alert after the voluntary withdrawal of tazemetostat indications for follicular lymphoma and epithelioid sarcoma, emphasizing the drug's association with secondary primary maligna…
- Immunotherapy trials like PODIUM-303 are reshaping treatment for squamous cell anal cancer, says Dr ParikhDr Aparna R. Parikh, an oncologist at Massachusetts General Hospital and Harvard professor, highlighted the growing feasibility of immunotherapy studies in squamous cell anal carcinoma (SCAC). She…